Evidence labels explain what kind of source is being read.
Dictionary / Evidence method
Preclinical evidence
Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes.
Evidence methodterm category
8related public pages
editorial navigationdefinition status
draftreview status
71exact evidence rows
56exact source links
1052nearby evidence rows
739nearby source links
1do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Preclinical evidence explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
56 direct sources linked to approved workbench claims. PubMed 39528623
1052 nearby evidence rows and 739 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Preclinical evidence is used in this encyclopedia as a evidence method term. Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes.
Evidence-method terms describe how a source should be read. They help separate human trials, observational work, preclinical work, mechanistic studies, and explicit evidence gaps.
Also searched as: animal evidence, animal study, cell study, cellular evidence.
Do not confuse with:
Evidence Guardrail
How to read it without overreaching
Use this term to classify the kind of evidence, not to inflate it. A stronger-sounding label still needs source details, study context, outcome measures, and limits.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 39528623
Distinct source records under those exact rows. PubMed 39528623
Source-backed public pages where this vocabulary is likely useful. Open related page
Evidence rows available on those related public pages. Open related page
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 39528623
- Open related pages.Use nearby pages for broader source-backed context. Related page
- Keep the boundary.A method label describes evidence type; it does not make the evidence stronger.
Exact Evidence Rows
Approved source-backed rows linked to this term
71 exact rows
No matching evidence rows.
Evidence Group
Preclinical
71 exact rows / 56 sources
Evidence row 10 / evidence context
CBN increases Total sleep time.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Evidence class is preclinical.
Evidence row 11 / evidence context
CBN increases NREM sleep.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Evidence class is preclinical.
Evidence row 12 / evidence context
CBN increases REM sleep.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Evidence class is preclinical.
Evidence row 33 / evidence context
CBG studied for Pain-related outcomes.
preclinical / very_low confidence.
Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. PubMed 39322049
Evidence class is preclinical.
Evidence row 36 / evidence context
CBC studied for Inflammation-related outcomes.
preclinical / very_low confidence.
The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. PubMed 37332213
Evidence class is preclinical.
Evidence row 65 / evidence context
CBG studied for Pain-related outcomes.
preclinical / very_low confidence.
Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. PubMed 35994012
Evidence class is preclinical.
Evidence row 66 / evidence context
CBG studied for Pain-related outcomes.
preclinical / very_low confidence.
Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. PubMed 34577072
Evidence class is preclinical.
Evidence row 73 / evidence context
CBC studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. PubMed 39921943
Evidence class is preclinical.
Evidence row 89 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
preclinical / very_low confidence.
Determination of Cannabinoids in Meat Products and Animal Feeds in Singapore Using Liquid Chromatography-Tandem Mass Spectrometry. PubMed 39200508
Evidence class is preclinical.
Evidence row 110 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
preclinical / very_low confidence.
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. PubMed 35364618
Evidence class is preclinical.
Evidence row 112 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
preclinical / very_low confidence.
Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PubMed 24282673
Evidence class is preclinical.
Evidence row 113 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
preclinical / very_low confidence.
Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin. PubMed 29588939
Evidence class is preclinical.
Evidence row 116 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
preclinical / very_low confidence.
Preclinical safety and efficacy of cannabidivarin for early life seizures. PubMed 30633929
Evidence class is preclinical.
Evidence row 124 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
preclinical / very_low confidence.
The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia. PubMed 41159452
Evidence class is preclinical.
Evidence row 128 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
preclinical / very_low confidence.
Evaluation of Sex Differences in the Potential of Δ9-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats. PubMed 35984924
Evidence class is preclinical.
Evidence row 132 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
preclinical / very_low confidence.
Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. PubMed 26439367
Evidence class is preclinical.
Evidence row 134 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
preclinical / very_low confidence.
Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping. PubMed 26381155
Evidence class is preclinical.
Evidence row 135 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
preclinical / very_low confidence.
Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid. PubMed 24012649
Evidence class is preclinical.
Evidence row 171 / evidence context
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Evidence class is preclinical.
Evidence row 172 / evidence context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Evidence class is preclinical.
Evidence row 174 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Evidence class is preclinical.
Evidence row 191 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
preclinical / very_low confidence.
Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring. PubMed 41840986
Evidence class is preclinical.
Evidence row 203 / evidence context
CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms.
preclinical / very_low confidence.
Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. PubMed 34179865
Evidence class is preclinical.
Evidence row 213 / evidence context
THC modulates receptor, target, or pharmacology mechanisms.
preclinical / very_low confidence.
Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. PubMed 30550613
Evidence class is preclinical.
Evidence row 223 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. PubMed 36603937
Evidence class is preclinical.
Evidence row 261 / evidence context
CBD modulates receptor, target, or pharmacology mechanisms.
preclinical / very_low confidence.
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. PubMed 22585736
Evidence class is preclinical.
Evidence row 269 / evidence context
THC studied for Cannabinoids and immune modulation research outcomes.
preclinical / very_low confidence.
Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring. PubMed 36746342
Evidence class is preclinical.
Evidence row 280 / evidence context
CBD studied for receptor, target, or pharmacology mechanisms.
preclinical / very_low confidence.
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. PubMed 34384142
Evidence class is preclinical.
Evidence row 306 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
preclinical / very_low confidence.
Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. PubMed 24346263
Evidence class is preclinical.
Evidence row 313 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
preclinical / very_low confidence.
Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. PubMed 30075103
Evidence class is preclinical.
Evidence row 353 / evidence context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. PubMed 40643195
Evidence class is preclinical.
Evidence row 356 / evidence context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. PubMed 40176500
Evidence class is preclinical.
Evidence row 550 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner. PubMed 40523564
Evidence class is preclinical.
Evidence row 586 / evidence context
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. PubMed 39322049
Evidence class is preclinical.
Evidence row 588 / evidence context
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. PubMed 39921943
Evidence class is preclinical.
Evidence row 590 / evidence context
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. PubMed 39699828
Evidence class is preclinical.
Evidence row 598 / evidence context
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model. PubMed 39009468
Evidence class is preclinical.
Evidence row 602 / evidence context
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. PubMed 40943856
Evidence class is preclinical.
Evidence row 603 / evidence context
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. PubMed 39128189
Evidence class is preclinical.
Evidence row 605 / evidence context
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. PubMed 32996187
Evidence class is preclinical.
Evidence row 607 / evidence context
CBG studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Evidence class is preclinical.
Evidence row 626 / evidence context
CBG studied for Appetite and metabolic outcomes.
preclinical / very_low confidence.
Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. PubMed 27503475
Evidence class is preclinical.
Evidence row 628 / evidence context
CBG studied for Appetite and metabolic outcomes.
preclinical / very_low confidence.
A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats. PubMed 28125508
Evidence class is preclinical.
Evidence row 630 / evidence context
CBG studied for Appetite and metabolic outcomes.
preclinical / very_low confidence.
Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. PubMed 31035309
Evidence class is preclinical.
Evidence row 635 / evidence context
CBG studied for Appetite and metabolic outcomes.
preclinical / very_low confidence.
Ensiling conditions and changes of cannabinoid concentration in industrial hemp. PubMed 39192735
Evidence class is preclinical.
Evidence row 643 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Evidence class is preclinical.
Evidence row 644 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Evidence class is preclinical.
Evidence row 646 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Evidence class is preclinical.
Evidence row 685 / evidence context
CBC studied for Pain-related outcomes.
preclinical / very_low confidence.
The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. PubMed 37332213
Evidence class is preclinical.
Evidence row 688 / evidence context
CBC studied for Pain-related outcomes.
preclinical / very_low confidence.
Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. PubMed 39921943
Evidence class is preclinical.
Evidence row 692 / evidence context
CBC studied for Pain-related outcomes.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Evidence class is preclinical.
Evidence row 698 / evidence context
CBC studied for Pain-related outcomes.
preclinical / very_low confidence.
Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests. PubMed 38255191
Evidence class is preclinical.
Evidence row 703 / evidence context
CBC studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Evidence class is preclinical.
Evidence row 704 / evidence context
CBC studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Evidence class is preclinical.
Evidence row 720 / evidence context
CBC studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
Biological activity of cannabichromene, its homologs and isomers. PubMed 7298870
Evidence class is preclinical.
Evidence row 731 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
preclinical / very_low confidence.
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. PubMed 20332000
Evidence class is preclinical.
Evidence row 744 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Evidence class is preclinical.
Evidence row 747 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preclinical / very_low confidence.
Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. PubMed 42151379
Evidence class is preclinical.
Evidence row 800 / evidence context
THCV studied for Pain-related outcomes.
preclinical / very_low confidence.
Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. PubMed 42151379
Evidence class is preclinical.
Evidence row 974 / evidence context
Cannabinoids modulates TRPV1.
preclinical / very_low confidence.
The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels. PubMed 40465624
Evidence class is preclinical.
Evidence row 1091 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. PubMed 38052772
Evidence class is preclinical.
Evidence row 1154 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. PubMed 15763177
Evidence class is preclinical.
Evidence row 1176 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide. PubMed 36733808
Evidence class is preclinical.
Evidence row 1178 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. PubMed 18316044
Evidence class is preclinical.
Evidence row 1182 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome. PubMed 36316276
Evidence class is preclinical.
Evidence row 1187 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation. PubMed 31881191
Evidence class is preclinical.
Evidence row 1194 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
N-Stearoylethanolamine Exerts Cardioprotective Effects in Old Rats. PubMed 38279735
Evidence class is preclinical.
Evidence row 1196 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
[Effects of N-stearoylethanolamine on the emotionality and learning ability of rats]. PubMed 25566671
Evidence class is preclinical.
Evidence row 1198 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
[Immunosuppressive characteristics of N-stearoylethanolamine a stable compound with cannabimimetic activity]. PubMed 18710028
Evidence class is preclinical.
Evidence row 1199 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
[Anti-inflammatory effect of N-stearoylethanolamine in experimental burn injury in rats]. PubMed 19873884
Evidence class is preclinical.
Evidence row 1201 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Exploring the Utility of Hair Endocannabinoids for Monitoring Homeostasis in Bonobos. PubMed 33434116
Evidence class is preclinical.
Source-Backed Connections
Related pages in the current encyclopedia
target
CB1
339 evidence rows / 255 sources
target
CB2
269 evidence rows / 196 sources
target
TRPV1
144 evidence rows / 96 sources
target
TRPA1
65 evidence rows / 37 sources
target
TRPM8
61 evidence rows / 28 sources
target
GPR55
59 evidence rows / 47 sources
target
TRPV2
58 evidence rows / 30 sources
target
FAAH
57 evidence rows / 50 sources
Nearby Terms